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Abstract: The low-spin 5d
6
 Ir
III
 organometallic half-sandwich complexes 
[(η5-Cpx)Ir(XY)Cl]0/+, Cpx = Cp*, tetramethyl(phenyl)cyclopentadienyl (Cpxph) or 
tetramethyl(biphenyl)cyclopentadienyl (Cp
xbiph
), XY = 1,10-phenanthroline (4, 5, 6), 
2,2'-bipyridine (7, 8, 9), ethylenediamine (10, 11), or picolinate (12, 13, 14), 
hydrolyze rapidly. Complexes with N,N- chelating ligands readily form adducts with 
9-ethylguanine but not 9-ethyladenine; picolinate complexes bind to both purines. 
Cytotoxic potency towards A2780 human ovarian cancer cells increases with phenyl 
substitution on Cp*: Cp
xbiph
 > Cp
xph
 > Cp*; Cp
xbiph
 complexes 6 and 9 have 
submicromolar activity. Guanine residues are preferential binding sites for 4–6 on 
plasmid DNA. Hydrophobicity (log P), cell and nucleus accumulation of Ir correlate 
with cytotoxicity, 6 > 5 > 4; they distribute similarly within cells. Ability to displace 
DNA intercalator ethidium bromide from DNA correlates with cytotoxicity and 
viscosity of Ir-DNA adducts. Hydrophobicity and intercalative ability of Cp
xph
 and 
Cp
xbiph
 make a major contribution to the anticancer potency of their Ir
III
 complexes. 
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a
Abbreviations: Cp*, pentamethylcyclopentadienyl; Cp
xph
, 
tetramethyl(phenyl)cyclopentadienyl; Cp
xbiph
, tetramethyl(biphenyl)cyclopentadienyl; 
9-EtG, 9-ethylguanine; 9-EtA, 9-ethyladenine; IC50, half-maximum inhibitory 
concentration. 
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Introduction 
The clinical success of cisplatin, carboplatin and oxaliplatin
1
 has stimulated the 
search for other transition metal complexes which possess anticancer activity. New 
metal-based anticancer drugs may be able to widen the spectrum of treatable cancers, 
reduce toxic side-effects, and overcome platinum resistance. Interest in 
bio-organometallic chemistry and the design of organometallic complexes as 
anticancer agents is currently increasing.
2
 Carbon-bound π-bonded arenes and 
cyclopentadienyl ligands can provide control of the hydrophilicity and hydrophobicity 
of the faces of the coordination complex (which influences cell uptake and targeting).
3
 
Most metallodrugs are prodrugs and control over ligand substitution is vital if the 
complex is to reach and react with its target site. In this respect octahedral low-spin d
6
 
complexes are attractive for drug design since they are often kinetically-inert. 
Inertness increases from 1
st
 to 2
nd
 to 3
rd
 row of transition metals.
4
 The lifetime for 
exchange of an aqua ligand on [Ir(H2O)6]
3+
, for example, is about 300 years!
5
 There 
are only a limited number of reported studies on the biological activity of iridium 
complexes. Early studies were concerned with non-organometallic Ir
I
 and Ir
III
 
complexes,
6
 and more recently a few studies of organometallic Ir
III
 complexes have 
been reported.
7
 Iridium(III) complexes are generally thought to be too inert to possess 
high reactivity. Indeed, the inertness of Ir
III 
has allowed the design of complexes 
which function as rigid scaffolds and inhibit kinase enzymes, for example.
8
 The 
biological inactivity of trans-[IrCl4(DMSO)(Im)][ImH]
9
 and trans-[IrCl4(Im)2][ImH] 
(ImH = imidazole)
10
, Ir
III
 analogs of the Ru
III
 anticancer drugs NAMI-A and the 
imidazole analogue of the indazole complex KP1019, respectively, has been attributed 
to the kinetic inertness of Ir
III
.  
Organometallic Ru
II
 and Os
II
 arene anticancer complexes of the type 
[(η6-arene)(Ru/Os)(NN)Cl]+, where NN is a chelating diamine ligand, can be 
activated by hydrolysis of the Ru/Os–Cl bond, followed by binding to DNA.11 The 
arene is important in determining the anticancer activity and nature of the DNA 
distortions. In particular when the arene is an extended -system (e.g. biphenyl or 
 4 
tetrahydroanthracene) direct binding to DNA bases (largely guanine) can be 
accompanied by arene intercalation between the bases.
12
  
Neutral arene ligands do not stabilize Ir
III
. In contrast, negatively-charged 
pentamethylcyclopentadienyl (Cp*)
a
 is an excellent stabilizing ligand for Ir
III
. In the 
work reported here we apply the design concepts discovered for Ru
II
 and Os
II
 arene 
complexes to Ir
III
 Cp* and functionalized Cp* complexes [(η5-Cpx)Ir(XY)Cl]0/+ 
containing N,N-bound 1,10-phenanthroline (phen), 2,2′-bipyridine (bpy), 
ethylenediamine (en), and N,O-bound picolinate (pico) as chelating ligands. 
Iridium(III) Cp* complexes have attracted recent attention as catalysts, for example in 
hydrogen transfer reactions.
13
 Only a few iridium complexes containing 
functionalized Cp* ligands have been reported previously.
14
 We have studied the 
effect of Cp* functionalization on the rate of hydrolysis, acidity of the aqua adducts, 
interactions with nucleobases, hydrophobicity (octanol/water partition), cell 
accumulation (the net effect of uptake and efflux) and distribution, interaction with 
DNA, and cytotoxicity to cancer cells.
15
 We show that such complexes can be 
thermodynamically stable and yet kinetically labile towards substitution reactions and 
that substituents on the cyclopentadienyl ring and chelating ligand can have a 
dramatic effect on chemical and biological activity. This appears to be the first time 
that Cp
xph
 and Cp
xbiph
 have been used as ligands in iridium complexes. 
 
Results 
Chemistry 
Syntheses. Eleven Ir
III
 half-sandwich complexes of the type [(η5-Cpx)Ir(XY)Cl]0/+, 
where Cp
x
 is pentamethylcyclopentadienyl, Cp*, or its phenyl Cp
xph
 or biphenyl 
Cp
xbiph 
derivatives, and XY is the N,N- chelating ligand 1,10-phenanthroline (phen, 4, 
5 and 6), 2,2'-bipyridine (bpy, 7, 8 and 9), ethylenediamine16 (en, 10 and 11), or N,O- 
chelating picolinate (pico, 12, 13 and 14), were synthesized, characterized, and their 
cancer cell cytotoxicity investigated. Their structures were studied by X-ray 
crystallography and by DFT calculations, and their aqueous solution chemistry with 
 5 
hydrolysis measurements, pKa determination for aqua adducts and interactions with 
nucleobases guanine and adenine. To elucidate the pronounced effect of the Cp
x
 
ligand on biological activity, detailed comparisons were made between the three phen 
complexes 4, 5, and 6 involving partition coefficients, distribution in cancer cells, 
DNA replication mapping, ethidium bromide displacement from DNA and effect on 
DNA viscosity.  
 
Chart 1. Iridium Cyclopentadienyl Complexes Studied in This Work. 
NN
Ir
Cpx
Z
0 / n+
CpxH
N N
bpy
NH2H2N
en
N
O
O
pico
Cp*H CpxphH CpxbiphH
_
Ir Cl
Cl Ir
Cl Cl
Cpx
Cpx
dimer
phen
XY
X
Y
Cpx
Cpxph
Cpxbiph
2
3
Cp* 1
 
Z=Cl Z=D2O/H2O       Z=9-EtG Z=9-EtA Cp
X XY 
4 4A 4G  Cp* phen 
5 5A 5G  Cpxph phen 
6 6A 6G  Cpxbiph phen 
7 7A 7G  Cp* bpy 
8 8A 8G  Cpxph bpy 
9 9A 9G  Cpxbiph bpy 
10 10A 10G  Cp* en 
11  11G  Cpxph en 
12 12A 12G 12Ad Cp* pico 
13 13A 13G 13Ad Cpxph pico 
14 14A 14G 14Ad Cpxbiph pico 
 
Complexes 4−14 were synthesized in moderate yields by reaction of 
1,10-phenanthroline, 2,2′-bipyridine, ethylenediamine, or 2-picolinate, with the 
appropriate dimer [(η5-Cpx)IrCl2]2  in methanol. The derivative Cp
xbiph
H, in which 
one of the ring methyls of Cp* is replaced by a biphenyl group, has not been 
previously reported. All the synthesized complexes were fully characterized by 
1
H 
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NMR spectroscopy and CHN elemental analysis. Introduction of phenyl substituents 
on the Cp* ring decreased the reaction yields significantly. Complexes 4 and 7 were 
isolated as Cl
−
 salts, complex 11 as a BPh4
−
 salt, and complexes 5, 6, 8, 9 and 10 as 
PF6
−
 salts. The complexes studied in this work are shown in Chart 1. 
X-ray Crystal Structures and Computation. The X-ray crystal structures of 
[(η5-C5Me4C6H5)IrCl2]2 (2), [(η
5
-C5Me4C6H5)Ir(phen)Cl]PF6
 
(5·PF6) 
[(η5-C5Me4C6H5)Ir(bpy)Cl]PF6
 
(8·PF6), [(η
5
-C5Me4C6H4C6H5)Ir(bpy)Cl]PF6
 
(9·PF6), 
[(η5-C5Me4C6H5)Ir(en)Cl]BPh4 (11·BPh4) and [(η
5
-C5Me4C6H5)Ir(pico)Cl] (13) were 
determined. The complexes adopt the expected half-sandwich pseudo-octahedral 
―three-leg piano-stool‖ geometry with the iridium bound to an η5-cyclopentadienyl 
ligand (Ir to ring centroid 1.747−1.789 Å), a chloride (2.384−2.415 Å) and a chelating 
ligand. Their structures and atom numbering schemes are shown in Figure 1 and 
Figure S1. Crystallographic data are shown in Table S1, and selected bond lengths 
and angles are listed in Table S2. 
In the structure of the Cp
xph
 dimer 2, one of the chlorides (Cl1 or Cl2) acts as a 
bridging ligand to a symmetry-related molecule across an inversion center. The Ir−Ir 
bond distance is 3.7157(4) Å and the angle between mean planes through the phenyl 
and the cyclopentadienyl groups is 68.21°. The phenyl group is involved in a weak 
π-π interaction with a symmetry-related phenyl group of a neighboring ligand in the 
unit cell (Figure S2). The two interacting π systems are parallel, with a 
centroid−centroid distance of 3.956 Å. Further intermolecular ring stacking is 
observed in the crystal structures of complex 5·PF6, between phen ligands in 
neighboring molecules (3.518 Å), Figure S3.  
The structures of the Ir
III
 complexes 5·PF6, 8·PF6 and 9·PF6 containing chelated 
phen or bpy are shown in Figure 1. The Ir−Cl and Ir−N bond lengths range from 
2.3840(14) to 2.3891(5) Å and from 2.083(6) to 2.1001(17) Å, respectively (Table 
S2). Stacking between the Cp
xbiph
 of neighboring molecules is present in crystals of 
complex 9·PF6. The centroids of the three rings on independent molecules are 
separated by 4.447, 4.607 and 4.447 Å, at dihedral angles of 8.47, 0 and 8.47°, 
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respectively, Figure S4. The twist angle between the cyclopentadienyl and the central 
ring is 45.23°, and between the central and the terminal phenyl ring is 46.34°. In 
contrast, the planes of the terminal and bound rings are only twisted by 8.47°. 
 
 
 
 
Figure 1. X-ray crystal structures with atom numbering schemes for (A) 
[(η5-C5Me4C6H5)Ir(phen)Cl]PF6
 
(5·PF6), (B) [(η
5
-C5Me4C6H5)Ir(bpy)Cl]PF6
 
(8·PF6), 
(C) [(η5-C5Me4C6H4C6H5)Ir(bpy)Cl]PF6
 
(9·PF6), (D) [(η
5
-C5Me4C6H5)Ir(en)Cl]BPh4 
(11·BPh4), and (E) [(η
5
-C5Me4C6H5)Ir(pico)Cl] (13), with thermal ellipsoids drawn at 
50% probability. The hydrogen atoms and counterions have been omitted for clarity. 
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The propeller twist of the phenyl-tetramethylcyclopentadienyl ligand in complex 
11·BPh4 is 63.7°. The Ir−Cl bond length (2.4152(12) Å) is the longest of these five 
X-ray structures. 
The geometries of complexes 4–14 were optimized using the PBE0 functional 
(Table S3, the description of frontier orbitals is in the Supporting Information). 
Selected calculated bond lengths are listed in Table S4 and are in good agreement 
with the experimental X-ray structures in the case of 5·PF6, 8·PF6, 9·PF6 and 11·BPh4. 
DFT calculations show that Ir–Cl and Ir–cyclopentadienyl ring bond distances remain 
similar on changing Cp* to substituted Cp* groups.  
 
 
 
Figure 2. Electrostatic potential surfaces of the phen chlorido complexes 4–6 and 
aqua adduct 6A, and the pico chlorido complexes 12–14 and aqua adduct 14A. EPS 
surfaces are shown both in space (with positive and negative regions in blue and red, 
respectively) and mapped on electron density (isovalue 0.004) of the molecules. The 
electrostatic potential is represented with a color scale going from red (–0.100 au) to 
blue (0.150 au).  
 
Electrostatic potential surfaces (EPS) for phen chlorido complexes 4−6 and aqua 
adduct 6A, and the pico chlorido complexes 12−14 and aqua adduct 14A were 
calculated. N,N-chelating phen complexes 4−6 show more positive electrostatic 
potentials than the N,O-chelating pico complexes 12−14 (Figure 2). Moreover, higher 
electron density is present on the second phenyl ring of the Cp
xbiph
 ligand in 
complexes 6 and 14. The same trend is observed in the electrostatic potential surfaces 
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of the aqua derivatives [(η5-C5Me4C6H4C6H5)Ir(phen)(H2O)]
2+
 (6A) and 
[(η5-C5Me4C6H4C6H5)Ir(pico)(H2O)]
+
 (14A), which as expected show more positive 
surfaces compared to their chlorido analogues, 6 and 14. 
Hydrolysis Studies. Hydrolysis of M–Cl bonds can represent an activation step for 
transition metal anticancer complexes.
17
 M–OH2 aqua complexes are often more 
reactive than the relevant chlorido complexes.
18
 The hydrolysis of compounds 4–10 
and 12–14 in 5% MeOD-d4/95% D2O (v/v) was monitored by 
1
H NMR at different 
temperatures from 278 to 293 K. The presence of methanol ensured the solubility of 
the complexes.  
All these Ir
III
 complexes undergo relatively rapid hydrolysis. Complexes 
[(η5-C5Me5)Ir(phen)Cl]
+
 (4), [(η5-C5Me5)Ir(bpy)Cl]
+
 (7), [(η5-C5Me5)Ir(en)Cl]
+
 (10) 
containing Cp*, and [(η5-C5Me5)Ir(pico)Cl] (12), [(η
5
-C5Me4C6H5)Ir(pico)Cl] (13) 
and [(η5-C5Me4C6H4C6H5)Ir(pico)Cl] (14) containing picolinate hydrolyzed too 
rapidly for the rates to be determined by 
1
H NMR spectroscopy even at 278 K: there 
was little change in the spectra between 5 min and 24 h, Figure S5. Attempts to 
observe hydrolysis of these complexes by UV-Vis at 288 K were also unsuccessful: 
equilibrium was reached before the first UV-Vis spectrum was acquired (< 1 min), 
Figure S6.  
To confirm the hydrolysis of these complexes, NaCl (1–4 mol equiv) was added to 
equilibrium solutions. With increase in NaCl concentration, 
1
H NMR peaks for the 
chlorido adducts increased whilst peaks for the aqua form decreased in intensity, 
Figures S7–S9. Similarly, addition of NaCl to an aqueous solution of the aqua 
complex 4A gave rise to peaks for the chlorido complex 4, Figure S10. 
The hydrolysis of complexes [(η5-C5Me4C6H5)Ir(phen)Cl]
+ 
(5), 
[(η5-C5Me4C6H4C6H5)Ir(phen)Cl]
+ 
(6), [(η5-C5Me4C6H5)Ir(bpy)Cl]
+ 
(8), 
[(η5-C5Me4C6H4C6H5)Ir(bpy)Cl]
+ 
(9), was slow enough to be studied by 
1
H NMR at 
low temperature. Hydrolysis was monitored at temperatures ranging from 278 K to 
293 K by observing the appearance of new 
1
H NMR peaks over time. The time 
dependence for formation of the aqua adducts of 5, 6, 8 and 9 was fitted to pseudo 
 10 
first-order kinetics (Figure S11), and their hydrolysis rate constants, half-lives and 
extent of hydrolysis were determined (Table 1). At 278 K, the half-life for hydrolysis 
of the biphenyl substituted Cp
xbiph
 complex 6 was 32 min, about 1.3 times slower than 
that of the phenyl-Cp* complex 5 (25 min; Table 1). The half-lives and extent of 
hydrolysis of complexes 4−6 at 278 K increase with the size of the ring system in the 
order Cp
xbiph
 > Cp
xph
 > Cp*. This trend is also observed for complexes 7−9. The 
hydrolysis rate constants and half-lives of 5, 6, 8 and 9 at 310 K (body temperature) 
were calculated using the Arrhenius equation and are listed in Table 1. These range 
from 1 min for complexes 5 and 8 to 4 min for complex 6.  
In each series of complexes containing different chelating N,N- or N,O- ligands, the 
equilibrium constants (Kaq) for hydrolysis at 278 K increased with increasing phenyl 
substitution on the Cp
x
 ligand, Table 1. 
 
Table 1. Hydrolysis Data for Complexes 4−10 and 12−14 at Various Temperatures  
 
Complex
a
 
k (min
−1
) 
t1/2 (min) 
Kaq 
(mM)
b 
 278 K 283 K 288 K 293 K 310 K
e
 
4 −
c
     0.04 
5 0.027 
25.4 
0.047 
14.6 
0.083 
8.3 
−
d 0.65 
1.1 
0.06 
6 0.022 
31.8 
−
d 0.044 
15.9 
0.065 
10.7 
0.18 
3.8 
0.29 
7 −
c
     0.05 
8 0.031 
22.1 
0.062 
11.1 
0.099 
7.0 
−
d
 
0.89 
0.8 
0.08 
9 0.026 
26.7 
0.041 
16.9 
−
d
 
0.078 
8.8 
0.23 
3.0 
1.45 
10 −
c
     0.44 
12 −
c
     0.78 
13 −
c
     1.11 
14 −
c
     2.33 
a
 The course of the hydrolysis of complex 11 was difficult to interpret from NMR spectra. 
b
 278 
K. 
c
 too fast to be measured.
d
 not determined. 
e 
obtained from Arrhenius equation.  
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The effect of added chloride on the aqueous chemistry of 7 was investigated. 
1
H 
NMR spectra of 1 mM 7 in 104, 23 or 4 mM NaCl in D2O (mimicking the chloride 
concentrations in blood plasma, cell cytoplasm and cell nucleus, respectively)
18b, 19
 
were recorded within 10 min of sample preparation and after incubation at 310 K for 
24 h. On the basis of 
1
H NMR peak integrals, almost no hydrolyzed complex 7 (7A) 
was found to be present in 104 mM [Cl] or in 23 mM [Cl], and only 5% of aqua 
complex 7A was observed at 4 mM [Cl] after 10 min with no further change after 24 
h. 
pKa* Determination. The pKa of coordinated water can have a significant 
influence on its reactivity since M−OH bonds are often much less labile than M−OH2 
bonds;
11b
 moreover hydroxide is a good bridging ligand and can give rise to 
oligomeric species.  
 
Table 2. pKa* and pKa Values
a
 for the Deprotonation of the Coordinated D2O in 
Complexes 4A−10A, and 12A−14A 
Aqua Complex pKa* pKa 
[(η5-C5Me5)Ir(phen)(D2O)]
2+ (4A) 7.88 7.74 
[(η5-C5Me4C6H5)Ir(phen)(D2O)]
2+ (5A) 7.68 7.55 
[(η5-C5Me4C6H4C6H5)Ir(phen)(D2O)]
2+ (6A) 7.50 7.38 
[(η5-C5Me5)Ir(bpy)(D2O)]
2+ (7A) 6.94 6.86 
[(η5-C5Me4C6H5)Ir(bpy)(D2O)]
2+ (8A) 6.31 6.28 
[(η5-C5Me4C6H4C6H5)Ir(bpy)(D2O)]
2+ (9A) 6.68 6.63 
[(η5-C5Me5)Ir(en)(D2O)]
2+ (10A) 7.66 7.54 
[(η5-C5Me5)Ir(pico)(D2O)]
+ (12A) 8.15 7.99 
[(η5-C5Me4C6H5)Ir(pico)(D2O)]
+ (13A) 7.75 7.62 
[(η5-C5Me4C6H4C6H5)Ir(pico)(D2O)]
+ (14A) 7.65 7.52 
a
 pKa values calculated from pKa* according to Krezel and Bal.
20 
Changes in the 
1
H NMR chemical shifts for coordinated chelating ligands in aqua 
complexes 4A−9A, 12A−14A, and methyl groups of Cp* in aqua complex 10A, were 
followed with change in pH* over a range of 2−11 (Figure S12). 1H NMR peaks 
 12 
assigned to aqua complexes gradually shifted to high field with increase in pH*. The 
resulting pH titration curves were fitted to the Henderson-Hasselbalch equation, from 
which the pKa* values of the coordinated water were determined. This gave rise to 
pKa values between 6.28 and 7.99 (Table 2), with the bpy complexes being the most 
acidic (pKa values 6.28−6.86) and the pico complexes the least acidic (pKa values 
7.52−7.99).  
Interactions with Nucleobases. Since DNA is a potential target site for transition 
metal anticancer complexes,
21
 the binding of 9-ethylguanine (9-EtG) and 
9-ethyladenine (9-EtA) to complexes 4−14, and aqua complex 5A were studied. The 
extent of nucleobase adduct formation by these complexes based on 
1
H NMR peak 
integrals is shown in Table 3.  
 
Table 3. Extent of 9-EtG and 9-EtA Adduct Formation for Complexes 4−14, and 5A 
(ca. 1 mM) at 310 K after 24 h 
 Cp
x
 XY 
G adduct  
(%) 
A adduct 
(%) 
4 Cp* phen(N,N-) 83  0 
5 Cp
xph
 phen(N,N-) 42  0 
5A Cp
xph
 phen(N,N-) 74  0 
6 Cp
xbiph
 phen(N,N-) 90  0 
7 Cp* bpy(N,N-) 61  0 
8 Cp
xph
 bpy(N,N-) 47  0 
9 Cp
xbiph
 bpy(N,N-) 65  0 
10 Cp* en(N,N-) 100  0 
11 Cp
xph
 en(N,N-) 100  0 
12 Cp* pico(N,O-) 100  81 
13 Cp
xph
 pico(N,O-) 100  76 
14 Cp
xbiph
 pico(N,O-) 100  71 
 
Addition of 1 mol equiv of 9-EtG to an equilibrium solution of complex 5, 
[(η5-C5Me4C6H5)Ir(phen)Cl]
+
 (1.0 mM), in 5% MeOD-d4/95% D2O (v/v, pH* 7.2) at 
310 K resulted in 15% of 5 reacting after 10 min, and a new 9-EtG H8 peak appearing 
at 7.68 ppm (species 5G, Figure S13), shifted by 0.15 ppm to high field relative to 
 13 
that of free 9-EtG. After 24 h, 42% of 5 had reacted. The ESI-MS of an equilibrium 
solution (Figure S14) contained a major peak at m/z 374.6, confirming the formation 
of the 9-EtG adduct 5G, [(η5-C5Me4C6H5)Ir(phen)(9-EtG)]
2+
 (calcd m/z 374.5). 
However, 65% of aqua complex 5A (prepared by treating a solution of 5 with 1 mol 
equiv of AgNO3) reacted with 9-EtG to form 5G after 10 min and 73% after 24 h. 
More than 80% of complexes 4 and 6 reacted with 9-EtG under the same conditions. 
Complexes [(η5-C5Me5)Ir(en)Cl]
+
 (10) and [(η
5
-C5Me4C6H5)Ir(en)Cl]
+
 (11) 
interestingly, showed an exceptionally high affinity for 9-EtG with 100% nucleobase 
adduct formation within 10 min. On addition of a solution of 1 mol equiv of 9-EtG 
gradually to an equilibrium solution of 10 (0.9 mM) in 5% MeOD-d4/95% D2O (v/v) 
at 310 K, Figure S15, the methyl peak for 10 and 10A decreased in intensity and 
eventually disappeared. A new Cp* methyl peak (for 10G) appeared at 1.65 ppm. 
When 9-EtG was in excess, a set of new peaks assignable to free 9-EtG was clearly 
visible (Figure S15). 
The geometry of the adduct (7G) between complex 7 and 9-EtG was optimized by 
DFT calculations. These gave an Ir–N7(9-EtG) distance of 2.14 Å. The Ir–N and 
Ir–cyclopentadienyl ring bond distances increase by 0.1–0.2 Å compared to complex 
7. The HOMO of the adduct is 9-EtG-centered and the LUMO has bpy character (see 
Table S3). 
Addition of 1 mol equiv of 9-EtA to an equilibrium solution of 5 (1.0 mM) in 5% 
MeOD-d4/95% D2O (v/v) at 310 K resulted in no additional 
1
H NMR peaks over a 
period of 24 h (Figure S16). Similarly, no reaction with 9-EtA was observed for other 
complexes containing N,N- chelating ligands (Table 3).  
In contrast, compounds 12−14 containing pico as chelating ligand formed both 
9-EtG and 9-EtA adducts to the extent of 100% and more than 70% completion, 
respectively, after 24 h. Two adenine nucleobase adducts are formed in the reaction of 
complexes 12, 13 and 14 with 9-EtA, most likely through iridium binding to N1 or N7 
of adenine forming 9-EtA adducts in 1:3.1, 1:3.2, and 1:3.0 ratios, respectively, 
Figure S17. 
 14 
Cancer Cell and DNA Studies 
Cytotoxicity. The cytotoxicity of complexes 4−14 towards A2780 human ovarian 
cancer cells was investigated, see Table 4. The IC50 values (concentration at which 50% 
of the cell growth is inhibited) for Cp* complexes 4, 7, 10, 12 and the Cp
xph
 pico 
complex 13 were all > 100 μM and are thus deemed as inactive. However, compounds 
5, 6, 8, 9, 11 and 14, were all active. Complexes 5, 8 and 11 containing Cp
xph
, and 14 
containing Cp
xbiph
 showed good activity, displaying IC50 values of 6−17 μM.  
Table 4. Inhibition of Growth of A2780 Human Ovarian Cancer Cells by Complexes 
4−14 and Comparison with Cisplatin 
Complex IC50
 a
 (μM) 
[(η
5
-C5Me5)Ir(phen)Cl]Cl (4·Cl) >100 
[(η
5
-C5Me4C6H5)Ir(phen)Cl]PF6
 
(5·PF6) 6.70 ± 0.62  
[(η
5
-C5Me4C6H4C6H5)Ir(phen)Cl]PF6
 
(6·PF6) 0.72 ± 0.01 
[(η
5
-C5Me5)Ir(bpy)Cl]Cl (7·Cl) >100 
[(η
5
-C5Me4C6H5)Ir(bpy)Cl]PF6
 
(8·PF6) 15.86 ± 1.49 
[(η
5
-C5Me4C6H4C6H5)Ir(bpy)Cl]PF6
 
(9·PF6) 0.57 ± 0.09 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
[(η
5
-C5Me5)Ir(en)Cl]PF6 (10·PF6) >100 
[(η
5
-C5Me4C6H5)Ir(en)Cl]BPh4 (11·BPh4) 16.97 ± 0.05 
[(η
5
- C5Me5)Ir(pico)Cl] (12) >100 
[(η
5
-C5Me4C6H5)Ir(pico)Cl] (13) >100 
[(η
5
-C5Me4C6H4C6H5)Ir(pico)Cl] (14) 16.30 ± 0.32 
Cisplatin 1.22 ± 0.12 
a
 Drug-treatment period was 24 h. 
Complexes 6 and 9 containing Cp
xbiph 
exhibited potent cytotoxicity with IC50 values 
of 0.7 and 0.6 µM, respectively, ca. twice as active as cisplatin in the A2780 cell line 
(IC50 1.2 µM). For all four series of complexes containing different chelating N,N- or 
N,O- ligands, the trend of increasing of activity with increasing phenyl substitution 
was the same: Cp
xbiph
 > Cp
xph
 > Cp*. 
  Hydrophobicity (log P). The octanol/water partition coefficients (log P) for the 
phen complexes 4−6 were determined since lipophilicity correlates with cytotoxic 
potency for some reported series of metallodrugs.
22
 The determined values are listed 
in Table 5. Addition of NaCl (200 mM) was used in order to suppress hydrolysis of 
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the compounds, ensuring that log P values for the chlorido and not aqua complexes 
were determined. The log P values increase in the order 4 < 5 < 6. Only complex 4, 
containing the unsubstituted Cp* ligand, has a negative log P value (partitions 
preferentially into water, Table 5). 
Table 5. log P Values for Complexes 4−6a  
 log P 
Complex mean SD 
4 –0.82 0.01 
5 0.48 0.03 
6 1.11 0.17 
a
Results are the mean of three independent experiments and are expressed as mean ± SD. 
 
Cell Accumulation and DNA Binding. Since increased lipophilicity has often 
been linked to increased cell uptake and cytotoxicity,
23
 the accumulation and DNA 
binding of complexes 4−6 by A2780 ovarian cancer cells was determined after 24 h of 
exposure to 5 μM concentrations of the complexes. DNA from A2780 cells was 
isolated and the Ir content was determined. The Cp
xbiph
 complex 6 gave rise to the 
highest level of iridium on DNA, ca. 4× that of complex 5, and 20× that of complex 4 
(Table 6). Of the total Ir taken up by the cells, 7.7% for 4, 5.5% for 5, and 6.0% for 6 
was bound to DNA.  
 
Table 6. Iridium Accumulation and Binding to DNA in A2780 Human Ovarian 
Cancer Cells
a
  
 
Complex 
cell accumulation 
(ng Ir/10
6
 cells) 
DNA binding 
(ng Ir/10
6
 cells) 
mean SD mean SD 
4 3.9 0.2 0.3 0.04 
5 23.5 3.7 1.3 0.3 
6 88.8 20.0 5.3 1.6 
a
 Drug-treatment period was 24 h with 5 μM Ir
III
 complexes. Each value represents the mean ± 
SD for two independent experiments done in triplicate. 
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Distribution of Iridium in Cell Fractions. The iridium content of the nucleus, 
cytosol, membrane and cytoskeleton fractions isolated from A2780 cells after 24 h of 
exposure to the phen complexes 4−6 was determined, and the results are shown in 
Table S5 and Figure 3. The extent of accumulation of the three complexes into the 
different cell fractions was similar to that observed for whole cell accumulation: 6 > 
5 > 4. The highest concentration of iridium was in the cell membrane/particulate 
fraction, accounting for 54% (6), 74% (5) and 59% (4) of the total Ir in the cell. For 
all complexes, the next highest concentration of Ir was in the cytosol, accounting for 
24% (6), 15% (5) and 17% (4).  
For the two remaining fractions, the Ir concentration dropped significantly. For 
complexes 4 and 6, the cytoskeleton was the next major compartment for Ir 
accumulation. The amount of Ir in the nucleus was significant and similar for all three 
Ir
III
 complexes: 7.2% of the total Ir for 6, 5.8% for 5, and 6.4% for 4, and similar in 
proportion to that bound to DNA. 
 
 
Figure 3. Iridium content of the nucleus, cytosol, membrane and cytoskeleton 
fractions (ng Ir/10
6
 cells) of A2780 cells after 24 h of exposure to 5 μM 4−6. Results 
are the mean of two independent experiments in triplicate and are expressed as mean 
± SD. 
Nucleus
Cytoskeleton
Cytosol
Membrane
Complex
 17 
  Replication Mapping of Iridium-DNA Adducts. This procedure involved the 
extension by VentR(exo-) DNA polymerase of the 3'-end of the primer up to the metal 
adduct on the template strand of pSP73KB DNA linearized by HpaI restriction 
endonuclease. The products of the synthesis were then examined on DNA sequencing 
gels, and the sequence specificity of iridium adduct formation was determined to the 
exact base pair. In vitro DNA synthesis on DNA templates containing the adducts of 
the phen complexes 4−6 generated a population of DNA fragments, indicating that the 
adducts of these complexes effectively terminated DNA synthesis (Figure 4A, lanes 
4−6). Complexes 4–6 exhibit a sequence dependence of the inhibition clearly different 
from that of cisplatin. The Ir compounds form more blocks on DNA for DNA 
polymerase than cisplatin and some of them occur at different sequences. These 
results are consistent with a less regular sequence specificity of complexes 4–6 in 
comparison with cisplatin. Identical patterns of blocks on DNA were observed if the 
template DNA was incubated with the metal complex for 8, 24 or 72 h (data not 
shown).  
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Figure 4. Replication mapping of Ir–DNA adducts. (A) Autoradiogram of 6% 
polyacrylamide/8 M urea sequencing gel showing inhibition of DNA synthesis by 
VentR DNA polymerase on the pSP73KB plasmid DNA linearized by HpaI 
restriction enzyme and subsequently modified by Ir
III
 complexes, cisplatin or 
transplatin. Lanes: control, unmodified template; A, T, G and C, chain-terminated 
marker DNAs (note that these dideoxy sequencing lanes give the sequence 
complementary to the template strand); 4−6, DNA modified by complexes 4−6 at rb = 
0.01, respectively; cisPt, DNA modified by cisplatin at rb = 0.01; transPt, DNA 
modified by transplatin at rb = 0.01. The numbers correspond to the nucleotide 
sequence in Figure 4B. (B) Schematic diagram showing a portion of the sequence 
used to monitor inhibition of DNA synthesis on the template containing adducts of 
(A)
(B)
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n
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t
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Ir
III
 complexes. The arrow indicates the direction of the synthesis. ○, major stop 
signals from Figure 4A, lanes 4−6. The numbering of the nucleotides in this scheme 
corresponds to the numbering of the nucleotides in the pSP73KB nucleotide sequence 
map.  
 
Ethidium Bromide (EtBr) Displacement. The ability of the complexes to 
displace the DNA intercalator EtBr from CT DNA was probed by monitoring the 
relative fluorescence of EtBr bound to DNA after treating the DNA with varying 
concentrations of 4−6. Figure 5 shows a plot of relative fluorescence vs rb for 
complexes 4−6, cisplatin and monofunctional 
chloridobis(2-aminoethyl)amineplatinum(II) chloride ([Pt(dien)Cl]Cl).  
 
 
Figure 5. Plots showing the dependence of EtBr fluorescence on rb for calf thymus 
DNA modified by Ir
III
 complexes 4−6, cisplatin, and [Pt(dien)Cl]Cl in 10 mM 
NaClO4 at 310 K for 24 h: (), complex 4; (), complex 5; (○), complex 6; (▲), 
cisplatin; (■), [Pt(dien)Cl]Cl. Data points measured in triplicate varied on average 
±3% from their mean. 
 
The adducts of monofunctional Ir
III
 complexes competitively replaced intercalated 
EtBr more effectively than the adducts of monofunctional [Pt(dien)Cl]Cl, but slightly 
less than the adducts of bifunctional cisplatin. Notably, the trend in ability to displace 
DNA intercalator EtBr from CT DNA was 6 > 5 > 4, which correlates with their 
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cytotoxicity (Table 4). 
Viscometry. The effects of complexes 4−6 on the viscosity of rod-like CT DNA 
(0.15 mg/mL or 0.47 mM in phosphorus content) are shown in Figure 6. On 
increasing the amounts of 4−6 bound to DNA (in the range of rb values of 0.005−0.04), 
the relative viscosity of CT DNA increased steadily; the effect follows the order 6 > 5 > 
4, which correlates with their cytotoxicity (Table 4) as well as with their ability to 
displace DNA intercalator EtBr from DNA (Figure 5). 
 
 
Figure 6. Plots showing the dependence of relative viscosity on rb for calf thymus 
DNA modified by Ir
III
 complexes 4−6. The viscosity was measured in 10 mM 
NaClO4, pH 6 at 310 K. (), complex 4; (), complex 5; (○), complex 6. 
 
Discussion 
The clinical success of cisplatin and related platinum anticancer drugs
1
 has led to 
the search for active complexes of other transition metals, especially to combat the 
limited spectrum of activity of platinum, drug resistance and side-effects. Can the 
design features found in platinum drugs be introduced into other transition metal 
complexes so as to rationalize the design process? From studies of organometallic 
half-sandwich arene complexes of the type [(η6-arene)M(diamine)Cl]+ (M = RuII or 
Os
II
), there is evidence that they can.
2c, 24
 These organometallic complexes contain an 
M−Cl bond which can be activated by hydrolysis and a neighboring NH group can 
stabilize binding to the nucleobase guanine via NH−C6O H-bonding. Unlike cisplatin, 
which contains two labile Pt−Cl bonds and can crosslink bases on DNA,1b these 
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complexes are monofunctional, but nevertheless can cause replication stop sites when 
bound to DNA, unlike monofunctional Pt
II
 adducts, such as [Pt(dien)Cl]Cl.
25
 Their 
strong selectivity for G versus A can be reversed by changing the NH group on the 
chelated ligand (e.g. ethylenediamine) to an H-bond acceptor oxygen such as in 
acetylacetonate.
26
 The interaction of Ru
II
 and Os
II
 arene complexes with DNA and 
their potency towards cancer cells can be increased by incorporating an extended 
arene which can intercalate between base pairs neighboring the metal coordination 
site.
25, 27
 
In the present work we sought to apply these design concepts to Ir
III
 complexes 
since the biological activity of iridium complexes has received relatively little 
attention.
6-7
 The low-spin d
6
 metal ion Ir
III
 is often described in the literature as totally 
inert, perhaps because water exchange on [Ir(H2O)6]
3+
 ions has long been known to 
take hundreds of years.
5a
 On the other hand it is also known that water exchange in 
[(η5-Cp*)Ir(H2O)3]
2+
 is ca. 10
14
 times faster.
28
 In general the dependence of ligand 
exchange reactions on the nature of the ligands in Ir
III
 complexes has been little 
studied. We have investigated Ir
III
 complexes containing Cp* ligands since they form 
highly stable Ir–C bonds, unlike arenes. The catalytic properties of IrIII Cp* 
complexes have recently been explored.
13, 29
 We have prepared the Cp* 
1,10-phenanthroline complex [(η5-Cp*)Ir(phen)Cl]+ (4, a complex recently reported to 
be inactive towards MCF-7 breast and HT-29 colon cancer cells),
30
 and compared its 
aqueous chemistry (hydrolysis and acidity of aqua adduct), nucleobase binding, 
transcription mapping, cytotoxicity towards A2780 human ovarian cancer cells, 
hydrophobicity (octanol/water partition), cellular distribution and DNA intercalation 
with that of related novel phen complexes containing phenyl- and 
biphenyl-substituted Cp* ligands (5 and 6), and with analogous complexes containing 
bipyridine (bpy, 7−9), or ethylenediamine (en, 10 and 11) as the N,N-chelating ligand, 
or picolinate (pico, 12−14) as an N,O-chelating ligand.  
Structures of the Complexes. A search of the Cambridge Database revealed that 
no structure of metal complexes containing the ligand Cp
xbiph
 has been reported. 
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Complex [(η5-C5Me4C6H4C6H5)Ir(bpy)Cl]PF6
 
(9·PF6) therefore appears to be the first 
such structure. The crystal structures of [(η5-C5Me4C6H5)IrCl2]2 (2), 
[(η5-C5Me4C6H5)Ir(phen)Cl]PF6
 
(5·PF6), [(η
5
-C5Me4C6H5)Ir(bpy)Cl]PF6
 
(8·PF6), 
[(η5-C5Me4C6H5)Ir(en)Cl]BPh4 (11·BPh4) and [(η
5
-C5Me4C6H5)Ir(pico)Cl] (13) are the 
first reported with (η5-C5Me4C6H5) (Cp
xph
 ) coordinated to iridium.  
The bond distances and angles in the dimer [(η5-C5Me4C6H5)IrCl2]2 (2) compare 
well to those found for the corresponding Cp* analogue [(η5-C5Me5)IrCl2]2 (1).
31 The 
Ir–Cl(bridging)–Ir and Cl(bridging)–Ir–Cl(bridging) angles in 2 are 1.2° more acute 
and obtuse, respectively, than those of the Cp* analogue. The Ir–Cl bond lengths in 
complexes 8·PF6 and 9·PF6 (2.3859(19) and 2.3840(14) Å, respectively, Table S2) are 
almost the same, however, the Ir–Cl bond length in complex 7 is slightly longer 
(2.404(2) Å)
32
. The twist angles in complex 9·PF6 are similar to those angles in Ru
II
 
terphenyl arene complexes.
27c
 The Ir–Cl bond length in complex 13 (2.3860(10) Å) is 
similar to that in complex 12 [(η5-C5Me5)Ir(pico)Cl] (2.3997(15) Å)
33
. 
The distance between Ir
III
 and the centroid of Cp ring in 
[(η5-C5Me4C6H5)Ir(phen)Cl]PF6
 
(5·PF6) (1.783 Å) is similar to that in 
[(η5-C5Me5)Ir(phen)Cl]CF3SO3 (1.780 Å)
34
, and the Ir−Cl bond length in 5·PF6 
(2.3891(5) Å) is similar to that in [(η5-C5Me5)Ir(phen)Cl]CF3SO3 (2.395 Å)
34
. On 
changing Cp* to substituted Cp* ligands, no significant change is observed by DFT 
calculations for Ir–Cl and Ir–cyclopentadienyl ring bond distances. These results 
suggest that the introduction of phenyl substituent on the Cp* ring does not give rise 
to significant change in structure.  
Hydrolysis and pKa of Aqua Adducts. There are only a few previous studies of 
the aquation of organometallic Ir
III
 complexes.
5a, 35
 In general, all the complexes 
studied in this work hydrolyze rapidly. Complexes 4, 7 and 10 containing Cp*, and 
12–14 containing picolinate hydrolyzed too rapidly to be observed by conventional 
UV-Vis at 288 K (t1/2 < 1 min). Even for omplex [(η
5
-C5Me4C6H4C6H5)Ir(phen)Cl]
+ 
(6), which hydrolyzed the slowest of these complexes, had a calculated half life at 310 
K of < 4 min (Table 1). These results illustrate that Ir
III
 complexes are not always inert 
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and can be quite labile. The hydrolysis of Ir–Cl bonds in iridium complexes is 
strongly dependent on the coordinated ligands. These Cp
x
 Ir
III
 complexes undergo 
even faster hydrolysis than low-spin d
6
 arene Ru
II
 and Os
II
 phen complexes,
11a,36 
more 
than 2 orders of magnitude faster than Os
II
 for example. The electron-donor methyl 
groups on the Cp ring may contribute to the fast hydrolysis. These increase the 
effective charge on Ir and facilitate chloride loss. This behavior is consistent with that 
of hexamethylbenzene Ru
II
 complexes.
37
  
Previous studies on the hydrolysis rates of Os
II
 arene compounds of the type 
[(η6-arene)Os(XY)Cl]n+ have shown that the aqueous reactivity of these complexes is 
highly dependent on the nature of the chelating ligand.
38
 In particular the 
negatively-charged electron-donating picolinate ligand increases the rate of hydrolysis 
compared to complexes with diamine ligands, as seen here for complexes 12–14.  
The presence of bpy as a π-acceptor in complex [(η6-bip)Ru(bpy)Cl]PF6, where bip 
= biphenyl, decreases the rate of hydrolysis by a factor of two compared to the en 
analogue.
36, 39
 The π-acceptor ligands bpy and phen can withdraw electron density 
from a metal center, increasing the positive charge on the metal, making it less 
favorable for Cl
−
 to leave, slowing down the hydrolysis. As a result, complexes 5, 6, 8 
and 9 containing bpy or phen as the chelating ligand hydrolyzed much more slowly 
than the en complex 10 and pico analogues, complexes 13 and 14. However, despite 
the electron withdrawing ability of bpy and phen, the hydrolysis rates of complexes 4 
and 7 are still relatively fast and appear to be controlled by the powerful electron 
donor Cp*. 
 
Our previous work has shown that the interaction of [(η6-bip)Ru(en)Cl]+ with 
amino acids,
40
 proteins,
40
 peptides,
41
 and DNA bases
11b
 involves aquation 
(substitution of Cl by H2O) as the first step. The anticancer drug cisplatin also 
undergoes aquation prior to platination of the target site, DNA.
18b, 42
 The equilibrium 
constants at 278 K for hydrolysis of complexes 4−6, 7−9, and 12−14, decrease in the 
order 6 > 5 > 4, 9 > 8 > 7, and 14 > 12, 13 (Table 1), which parallels their cytotoxicity 
(Table 4), perhaps indicating that activation by aquation is important for the 
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mechanism of their cytotoxic action. 
At chloride concentrations typical of blood plasma (104 mM) and cell cytoplasm 
(23 mM), the inactive complex [(η5-C5Me5)Ir(bpy)Cl]
+ 
(7) (IC50 > 100 M, Table 4) 
was found to be almost all present in solution as the intact chlorido species, which is 
relatively unreactive compared to the aqua complex 7A. At a chloride concentration 
of 4 mM, close to that of the cell nucleus, only about 5% of 7 was present as the 
reactive aqua species.  
When the pKa values of the aqua complexes (Table 2) are compared, it is evident 
that the presence of phenyl or biphenyl substitutent lowers the pKa value by ca. 0.4 
units consistent with withdrawal of electron density from the Ir center. Replacement 
of the π-acceptor ligand bpy in aqua complex 7A by the chelating diamine donor en in 
10A, leads to a significant increase in pKa by ca. 0.7 units, consistent with an 
increased electron density on the metal center. Similarly, the replacement of the 
neutral chelated bpy ligand by the anionic pico ligand raises the pKa by 1.1 units. 
There appears to be no correlation between the pKa values of the aqua adducts and the 
cytotoxicity of these complexes. The pKa values of the pico, en and phen aqua 
complexes 4A, 6A, 10A, 12A−14A suggest that they will be present largely as the 
reactive aqua adducts as opposed to the less reactive hydroxo adducts at physiological 
pH (7.4), whereas the pKa values of the bpy complexes 7A−9A are significantly lower, 
especially 8A, and therefore most of the hydrolyzed bpy complexes would be present 
as the hydroxido form (at pH 7.4). Despite this, complexes 8 and 9 exhibit good 
activity. Their reactivity would be aided by the small lowering of pH which is thought 
to occur in tumors.
43
  
For Ru
II
 complexes which contain biphenyl as the arene and bpy as chelating ligand, 
loss of the arene is observed in aqueous solution.
36
 In contrast no loss of any Cp
x
 
ligands was observed for any of the Ir
III
 complexes studied in this work. 
Interactions with Nucleobases. DNA is often a target for cytotoxic transition 
metal anticancer complexes.
21
 There is little reported work on interactions of iridium 
complexes with nucleobases.
44
 In the present study, the reactions of complexes 4−14, 
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and aqua complex 5A with 9-ethylguanine and 9-ethyladenine were investigated. 
Complexes 4−11 and 5A containing a neutral N,N- chelating ligand all bind 
selectively to 9-EtG compared to 9-EtA, with which no reaction was observed after 24 
h. This result is consistent with the replication mapping experiments (Figure 4) which 
show that G residues are the preferential binding sites on polymeric DNA modified 
with complexes 4−6. The less regular sequence specificity of complexes 4−6 in 
comparison with cisplatin might arise from the faster DNA binding of 4−6. The 
selectivity in nucleobase binding can be rationalized in terms of H-bonding, 
non-bonding repulsive interactions between the chelating ligand and nucleobase 
substituents, and the electronic properties of the various nucleobase coordination 
sites.
38a
 Our previous studies of Ru−N7 guanine adducts have revealed a strong 
H-bonding interaction between one en NH and G C6O.
11b
 This may explain the strong 
affinity of 9-EtG for the Ir
III
 en complexes 10 and 11. A phenanthroline ligand cannot 
provide a donor NH group, but instead the interaction with G C6O may be stabilized 
by a C−H H-bond similar to that observed in a bipyridine complex of RuII.36 This 
possibility was indicated by the DFT optimized structure of the 9-EtG adduct of 6 
(Figure S18).  
Complexes 4−11 containing an N,N-chelating ligand did not react with 9-EtA, most 
likely due to the steric hindrance of the NH2 group on the 6-position of the adenine 
ring. Compared to complexes containing an N,N-chelating ligand, compounds 12−14 
which contain the N,O- chelating ligand pico, bind significantly (70−100%) to both 
nucleobases, see Table 3. These picolinate Ir
III
 adducts of complexes 12, 13 and 14 
with 9-EtA (12Ad, 13Ad, and 14Ad, respectively) can be stabilized by hydrogen 
bonding between the NH2 group of adenine and a carboxylate oxygen of the 
picolinate ligand.
45
 
As expected, the aqua complex 5A reacted to a greater extent with 9-EtG compared 
to the chlorido complex 5, see Table 3, consistent with the increased reactivity of aqua 
adducts compared to their chlorido forms,
18a
 but the selectivity for G versus A was the 
same.  
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Hydrophobicity (log P) and Cell Accumulation. log P values for octanol/water 
partition provide a measure of hydrophobicity which is often a factor relevant for cell 
uptake and anticancer activity. For several classes of metallo-anticancer complexes, a 
correlation between increased hydrophobicity and increased cytotoxic activity has 
been reported.
22-23
   
In this study, as expected, the log P values (Table 5) and hydrophobicity increase 
with increasing size of the substituted Cp* ligand. Additionally, the hydrophobicity, 
cancer cell activity, and cell accumulation correlate significantly, following the order 
6 > 5 > 4. Complex [(η5-C5Me5)Ir(phen)Cl]
+ 
(4) is the least hydrophobic, the least 
cytotoxic, and the least taken up by the cells, whereas complex 
[(η5-C5Me4C6H4C6H5)Ir(phen)Cl]
+ 
(6) displays the highest hydrophobicity, is the most 
cytotoxic, and the most taken up by the cells. These data suggest that in the ovarian 
A2780 cancer cell line, the log P value is a useful parameter for predicting the 
cytotoxicity of this class of iridium complexes. These data also show that using more 
extended coordinated Cp
x
 ligands such as tetramethyl(biphenyl)cyclopentadienyl 
(Cp
xbiph
) gives rise to in increased hydrophobicity leading to higher cellular uptake 
and higher cytotoxicity. For Os
II
 arene complexes this range of log P values (–0.51 
and 0.86) is also accompanied by promising anticancer activity.
46
 Such complexes are 
hydrophobic enough to partition efficiently into cells and yet hydrophilic enough to 
exhibit reasonable aqueous solubility. 
Distribution of Iridium in Cells. The accumulation of the three phen complexes 
4–6 into the different cell fractions was studied. A significant proportion of the total 
iridium (54−74%) was in the cell membrane fraction, see Figure 3. This may be 
related not only to Ir being transported into the cytoplasm but also to Ir being 
exported by cells. For all complexes, the next highest concentration of iridium was 
found in the cytosol showing that passage through the outer membrane readily occurs.  
Although the lowest proportion of iridium was found in the nucleus, especially for 
complexes 4 and 6, it is notable that there is a correlation between nucleus 
accumulation and cytotoxicity of the complexes, both of which follow the order 6 > 5 > 
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4, suggesting that penetrating the nucleus and binding to nuclear DNA may provide an 
important contribution to the mechanism of cytotoxicity. A similar relationship 
between nucleus accumulation and cytotoxicity was observed for Os
II
 arene 
complexes.
46
  
DNA Binding in A2780 Carcinoma Cells. The amount of iridium found on the 
DNA of A2780 cells (Table 6) incubated with the complexes for 24 h follows the 
order 6 > 5 > 4, which correlates with their cytotoxicity, hydrophobicity (log P), and 
cellular accumulation (Table 6), and is similar to the total accumulation by cell nuclei. 
The extent of iridium binding of 4−6 to DNA, 5.5−7.7% of the total iridium taken up 
by the cells, is higher than that reported for cisplatin (~1%)
47
 and Os
II
 arene 
complexes.
46
 DNA may therefore be a potential target for these cytotoxic iridium 
complexes, although we cannot rule out the possibility that nuclear DNA may not be 
the only target.
48
  
EtBr Displacement and Viscometry. The fluorescent probe EtBr can be used to 
distinguish between intercalating and nonintercalating ligands.
25, 49
 Viscosity 
measurements are also useful for probing the nature of DNA interactions since 
viscosity is sensitive to alterations in DNA length. For instance, complexes or ligands 
that intercalate cause an increase in overall DNA contour length due to the increase in 
separation of base pairs at the intercalation sites, which leads to an increase in 
viscosity of DNA solutions. On the other hand, drug molecules which bind in DNA 
grooves cause less pronounced changes in the viscosity of DNA solutions.
50
 
Modification of CT DNA by complexes 4−6 resulted in a decrease of EtBr 
fluorescence intensity (Figure 5) and an increase in the relative viscosity of CT DNA 
(Figure 6) in the same order 6 > 5 > 4, which correlates with their cytotoxicity (IC50 
values). These results indicate that addition of phenyl substituents to the Cp* ring in 
these iridium complexes enhances the intercalative ability into DNA. Dual-mode 
intercalation/G N7 coordination DNA binding may therefore play an important role in 
the cytotoxicity of these Ir
III
 complexes. This observation parallels that of Ru
II
 and 
Os
II
 arene complexes for which extended arenes can also intercalate and increase the 
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potency of the complexes.
12a, 24c
 For example, the Ru
II
 anticancer complex 
[(η6-p-terp)Ru(en)Cl]+ (where p-terp = para-terphenyl, a similar arene ligand to 
Cp
xbiph
) also exhibits combined intercalative and monofunctional (coordination) 
binding to DNA.
27c
  
The DFT-computed electrostatic potential surfaces of the phen complexes 4–6 
show more positive values than those of pico complexes 12–14 (same trend for the 
aqua derivatives 6A and 14A). This may favor interaction with negatively charged 
DNA in the case of phen complexes. The higher electron density on the second 
phenyl ring of the Cp
xbiph
 ligands (Figure 2), together with the lower steric hindrance 
of the terminal phenyl ring, can explain the better intercalation properties of 6. 
Complex 6 is likely to be present in the nucleus largely as the aqua complex 6A which 
has an even higher positive charge distributed over its surface (Figure 2). 
Cytotoxicity. Complexes [(η5-C5Me5)Ir(phen)Cl]Cl (4·Cl), 
[(η5-C5Me5)Ir(bpy)Cl]Cl (7·Cl), [(η
5
-C5Me5)Ir(en)Cl]PF6 (10·PF6) and 
[(η5-C5Me5)Ir(pico)] (12) containing Cp* were non-toxic (IC50 > 100 μM) toward the 
human ovarian A2780 cancer cell line (Table 4). The cytotoxicity of complexes 
[(η5-C5Me4C6H5)Ir(phen)Cl]PF6
 
(5·PF6) and [(η
5
-C5Me4C6H4C6H5)Ir(phen)Cl]PF6
 
(6·PF6) containing phenyl and biphenyl substituents, respectively, on the 
tetramethylcyclopentadienyl ring increases dramatically compared to the parent Cp* 
complex 4. Complex 6 containing Cp
xbiph 
is ca. twice as potent towards A2780 human 
ovarian cancer cells as the anticancer drug cisplatin (Table 4). The introduction of 
phenyl and biphenyl substituents also resulted in significant increases in activity for 
complexes 7–9, 10–11 and 12–14, suggesting that these phenyl groups play a crucial 
role in the mechanism of action. This is consistent with our previous observations that 
the cytotoxicity of η6-arene RuII compounds increases with the size of the arene ring 
system in the order benzene < p-cymene < biphenyl < dihydroanthracene < 
tetrahydroanthracene.
3c
 The increase in potency on addition of phenyl substituents to 
the Cp ring, by about an order of magnitude for each of the additions (from 4 to 5 to 6) 
is more dramatic than in the case of ruthenium arene ethylenediamine complexes.
27c, 
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51
 For these iridium complexes, the phenyl substitutents not only enhance lipophilicity 
and cell accumulation, but also introduce an additional mode of DNA interaction 
(intercalation). 
Both complexes [(η5-C5Me4C6H5)Ir(bpy)Cl]
+ 
(8) and [(η5-C5Me4C6H5)Ir(pico)Cl] 
(13) contain Cp
xph
, however, 8 exhibits activity towards A2780 cancer cells whereas 
13 is inactive, which suggests that the chelating ligand also plays a role. Replacement 
of neutral bpy by anionic pico as the chelating ligand increases the rate and extent of 
hydrolysis, the pKa of the aqua complex (from 6.31 to 7.75 for ring = Cp
xph
, Table 2), 
and changes the nucleobase specificity. For complexes 7−9 containing neutral bpy, 
there is exclusive binding to 9-EtG. In contrast, complexes 12−14 containing anionic 
pico bind strongly to both 9-EtG and 9-EtA. These results are in agreement with 
previous work on Ru
II
 and Os
II
 complexes in which neutral en is replaced by 
negatively charged acetylacetonate (acac).
26, 38a
 The rapid hydrolysis, low acidity of 
aqua adducts and strong binding to biomolecules may account for the low cytotoxicity 
of the picolinate complexes. The highly reactive aqua species may interact with other 
cellular biomolecules before they reach target sites, thus effectively being deactivated. 
For example, the amino acids (methionine or cysteine) or tripeptides can form 
S-bound adducts with Ir
III 
Cp* complexes.
44a
 
Interestingly some ruthenium
27a
 and osmium
11a
 arene complexes containing phen or 
bpy derivatives show poor or no activity against A2780 cells. The inactivity of phen 
complex 4 and bpy complex 7 may be correlated with their low extent of hydrolysis 
and poor cellular accumulation. Although complex 7 may reach the cell nucleus, its 
hydrolysis is largely suppressed (only 5% hydrolyzed in the presence of 4 mM NaCl), 
and the complex therefore remains predominately as the less-reactive intact chlorido 
species. These factors may explain the inactivity of 4 and 7, and also the inactivity of 
10. 
 
Conclusions 
The goal of the present study was to explore the rational design of monofunctional 
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organometallic half-sandwich Ir
III
 anticancer complexes based on knowledge of the 
features which contribute to the activity of half-sandwich Ru
II
 and Os
II
 arene 
complexes.
2, 24a, 52
 The biological and medicinal chemistry of iridium complexes has 
been little explored previously,
6-7
 perhaps because it is often assumed that low-spin 
5d
6
 Ir
III
 complexes are highly kinetically inert.
5, 9-10
 Our data show that this is not 
always the case. Cyclopentadienyl ligands, whilst stabilizing Ir
III
, can confer kinetic 
lability on trans monodentate ligands such as chloride. Moreover phenyl substituents 
on the Cp* ring as in Cp
xph
 and Cp
xbiph
 can have a major effect on the chemical and 
biological behavior of [(η5-Cpx)Ir(XY)Cl]0/+ complexes. 
This appears to be the first time that Cp
xph
 and Cp
xbiph
 ligands have been used in 
iridium complexes. The crystal structure of complex 
[(η5-C5Me4C6H4C6H5)Ir(bpy)Cl]PF6
 
(9·PF6) appears to be the first reported structure 
containing the ligand Cp
xbiph
. The crystal structures of [(η5-C5Me4C6H5)IrCl2]2 (2), 
[(η5-C5Me4C6H5)Ir(phen)Cl]PF6
 
(5·PF6), [(η
5
-C5Me4C6H5)Ir(bpy)Cl]PF6
 
(8·PF6), 
[(η5-C5Me4C6H5)Ir(en)Cl]BPh4 (11·BPh4) and [(η
5
-C5Me4C6H5)Ir(pico)Cl] (13) are 
the first to be reported with η5-C5Me4C6H5 coordinated to iridium.  
Figure 7 provides an overview of the relationships between cancer cell cytotoxicity, 
intercalative ability, cellular accumulation, hydrophobicity, and rates and extents of 
hydrolysis for the phen complexes 4–6. Figure 8 shows how the chelating and Cpx 
ligands affect the anticancer activity, nucleobase binding, and aqueous chemistry of 
the bpy complexes 7–9 and pico complexes 12–14. These [(η5-Cpx)Ir(XY)Cl]0/+ 
complexes hydrolyze rapidly (the slowest half-life < 4 min at 310 K), and the nature 
of the cyclopentadienyl and chelating ligands significantly influence their aqueous 
chemistry. In general, the introduction of phenyl and biphenyl Cp* ring substituents 
slows down the hydrolysis rate, increases the extent of hydrolysis, and increases the 
acidity of the respective aqua species. The chelating ligand appears to determine the 
selectivity of nucleobase binding. The complexes containing N,N- chelating ligands 
discriminate strongly between the purine nucleobases guanine and adenine, showing 
little binding to the latter for either for Cp*, Cp
xph
 or
 
Cp
xbiph
 complexes. In contrast, 
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complexes 12−14 containing the N,O- chelating ligand picolinate bind both to 9-EtG 
and 9-EtA. 
 
 
Figure 7. Bar charts illustrating the relationship between cytotoxicity toward human 
cancer cells, intercalative ability, cellular accumulation, hydrophobicity, and rates 
(288 K) and equilibrium constants (278 K) of hydrolysis for iridium complexes 
[(η5-Cpx)Ir(phen)Cl]+ containing Cpx = Cp* (4), Cpxph (5), and Cpxbiph (6). 
 
Hydrolysis Equilibrium 
Constant
Hydrophobicity
3.9
23.5
88.8
0
50
100
1 2 3
Cellular Accumulation
100
6.7 0.72
0
50
100
150
1 2 3
Series1
>
Activity
Viscosity
Hydrolysis Rate
(288 K)
<1
25.4
31.8
0
15
30
45
1 2 3
Series1
1.032
1.056
1.106
0.98
1.05
1.12
1 2 3
-0.82
0.48
1.11
-1
-0.5
0
0.5
1
1.5
0.04
0.06
0.29
0
0.1
0.2
0.3
1 2 3
S…45
.1
0
30
15
0
0
100
η/η0
50
0.
1
t1/2
(min)
Ir
n
g
/1
0
6
ce
lls
 
IC50
(μM)
1.
1.
Kaq
.2
.3
.
Log P
 32 
 
Figure 8. Bar charts illustrating the influence of N,N- and N,O-chelating ligands on 
the cytotoxicity, nucleobase binding, hydrolysis and pKa of the aqua adducts of the 
bpy complexes 7–9, and pico complexes 12–14. 
 
The introduction of a phenyl substituent into the Cp* ring switches on cancer cell 
cytotoxicity. For example, the tetramethyl(phenyl)cyclopentadienyl complex 5 is 
more than one order of magnitude more potent than the pentamethylcyclopentadienyl 
complex 4, and the biphenyl complex 6 is more than 2 orders of magnitude more 
potent than complex 4, and twice as potent as cisplatin in the same cell line. This 
increase in activity parallels the increase in hydrophobicity, increase in cell 
accumulation and DNA binding. Complexes 5 and 6 can exhibit dual mode binding to 
DNA: iridium binding to G N7 accompanied by intercalation of the phenyl 
substituents on the Cp* ring. Significant increases in activity for complexes 7–9, 
10–11 and 12–14 are also observed. On the other hand, the chelating ligand can also 
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play an important role in the anticancer activity. For example, the pico complex 13 
shows no activity toward the A2780 cell line while the bpy analogue complex 8 
shows good activity, and the bpy complex 9 is more than one order of magnitude 
more potent than the pico analogue, complex 14. 
The work reported here demonstrates that rational chemical design can be applied 
to Ir
III
 complexes to achieve potent cancer cell cytotoxicity. It is notable that Cp ring 
substituents can also play a major role in controlling the chemical and biological 
properties of ferrocenyl and titanocenyl anticancer complexes.
53
 In general, 
organometallic complexes offer much promise for the design of novel therapeutic 
agents.
2, 24a, 52a
 
 
Experimental Section 
Details of the materials used and the synthesis and characterization of complexes 
are in the Supporting Information. The general synthetic route to the iridium 
complexes involved reaction of 1,10-phenanthroline, 2,2′-bipyridine, ethylenediamine, 
or 2-picolinate, with the appropriate dimer [(η5-Cpx)IrCl2]2  in methanol. CHN 
elemental analyses were carried out for all complexes and synthesized ligands, by 
which their purity were confirmed to be in excess of 97.0%. 
Methods and Instrumentation.  
X-ray crystallography. All diffraction data were obtained on an Oxford 
Diffraction Gemini four-circle system with a Ruby CCD area detector using Mo Kα 
radiation. Absorption corrections were applied using ABSPACK.
54
 The crystals were 
mounted in oil and held at 100(2) K with the Oxford Cryosystem Cobra. The 
structures were solved by direct methods using SHELXS (TREF)
55
 with additional 
light atoms found by Fourier methods. Complexes were refined against F
2
 using 
SHELXL
56
, and hydrogen atoms were added at calculated positions and refined riding 
on their parent atoms.  
X-ray crystallographic data for complexes 2, 5·PF6, 8·PF6, 9·PF6, 11·BPh4 and 13 
are available as Supporting Information and have been deposited in the Cambridge 
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Crystallographic Data Centre under the accession numbers CCDC 802289, 802288, 
802287, 802291, 802290, and 802286, respectively. 
NMR Spectroscopy. 1H NMR spectra were acquired in 5 mm NMR tubes at 298 K 
(unless stated otherwise) on either a Bruker DPX 400 (
1
H = 400.03 MHz) or AVA 600 
(
1
H = 600.13 MHz) spectrometers. 
1
H NMR chemical shifts were internally 
referenced to (CHD2)(CD3)SO (2.50 ppm) for DMSO-d6, CHCl3 (7.26 ppm) for 
chloroform-d1 or to 1,4-dioxane (3.75 ppm) for aqueous solutions. All data processing 
was carried out using XWIN-NMR version 3.6 (Bruker UK Ltd.). 
Mass Spectrometry. Electrospray ionization mass spectra (ESI-MS) were obtained 
by preparing the samples in 50% CH3CN and 50% H2O (v/v) and infusing into the 
mass spectrometer (Bruker Esquire 2000). The mass spectra were recorded with a 
scan range of m/z 50–1000 for positive ions.  
Elemental Analysis. CHN elemental analyses were carried out on a CE-440 
elemental analyzer by Exeter Analytical (UK) Ltd. 
pH Measurement. pH* values (pH meter reading without correction for effects of 
deuterium on glass electrode) of NMR samples in D2O were measured at ca. 298 K 
directly in the NMR tube, before and after recording NMR spectra, using a Corning 
240 pH meter equipped with a micro combination electrode calibrated with Aldrich 
buffer solutions of pH 4, 7 and 10.  
UV-Vis Spectroscopy. A Cary 300 UV-Vis recording spectrophotometer was used 
with 1 cm path-length quartz cuvettes (0.5 mL) and a PTP1 Peltier temperature 
controller. Spectra were processed using UVWinlab software. Experiments were 
carried out at 288 K unless otherwise stated. 
Kinetics of Hydrolysis. Solutions of complexes 4–10 and 12–14 with final 
concentrations of 0.2–0.7 mM in 5% MeOD-d4/95% D2O (v/v) were prepared by 
dissolution of the complexes in MeOD-d4 followed by rapid dilution with D2O. 
1
H 
NMR spectra were recorded after various time intervals. The rates of hydrolysis were 
determined by fitting plots of concentrations (determined from 
1
H NMR peak 
integrals) versus time to a first-order rate equation using ORIGIN version 8.1. The 
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hydrolysis of complexes 4, 7, 10, 12, 13 and 14 was monitored by 
1
H NMR at 278 K 
(to slow down the rate and avoid freezing the samples), and for complexes 5, 6, 8 and 
9 at 278, 283, 288 and 293 K. The Arrhenius equation ln(k) = ln(A) – Ea/RT was used 
to calculate the hydrolysis rate constants and half-lives of 5, 6, 8 and 9 at 310 K.  
Determination of pKa Values. To generate the aqua complexes, chlorido 
complexes were dissolved in D2O and 0.98 mol equiv of AgNO3 were added. The 
solution was stirred for 24 h at 298 K, and AgCl was removed by filtration. For 
determinations of pKa* values (pKa values for solutions in D2O) the pH* values of 
solutions of the aqua complexes in this study in D2O were varied from ca. pH* 2 to 11 
by the addition of dilute NaOD and DClO4, and 
1
H NMR spectra were recorded. The 
chemical shifts of the chelating ligand protons and/or methyl protons of Cp
x
 were 
plotted against pH*. The pH* titration curves were fitted to the 
Henderson-Hasselbalch equation, with the assumption that the observed chemical 
shifts are weighted averages according to the populations of the protonated and 
deprotonated species. These pKa* values can be converted to pKa values by use of the 
equation pKa = 0.929pKa* + 0.42 as suggested by Krezel and Bal
20
 for comparison 
with related values in the literature. 
Computational Details. The Gaussian 03 package
57
 was employed for all 
calculations. Geometry optimization calculations for complexes 4–14, aqua 
complexes 6A and 14A, and 9-ethylguanine (9-EtG) adduct 7G were performed in the 
gas phase with the gradient-corrected correlation functional PBE0.
58
 The LanL2DZ 
basis set and effective core potential
59
 were used for the Ir atom and the 6-31G** 
basis set was used for all other atoms.
60
 The nature of all stationary points was 
confirmed by performing a normal-mode analysis. Electrostatic potential surfaces 
(EPS) for complexes 4–6, 12–14, 6A and 14A were calculated and mapped on 
electron density (isovalue 0.004) of the molecules. The electrostatic potential is 
represented with a color scale ranging from red (–0.100 au) to blue (0.150 au). 
Interactions with Nucleobases. The reaction of complexes 4–14 and 5A (ca. 1 
mM) with nucleobases typically involved addition of a solution containing one mol 
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equiv of nucleobase in D2O to an equilibrium solution of complexes 4–14 in 5% 
MeOD-d4/95% D2O (v/v), or to a solution of the aqua complex 5A (prepared by the 
addition of 1 mol equiv of AgNO3 to a solution of 5 and removal of AgCl by 
filtration). 
1
H NMR spectra of these solutions were recorded at 310 K after various 
time intervals. 
ICP-MS Instrumentation and Calibration. All ICP-MS analyses were carried out 
on an Agilent Technologies 7500 series ICP-MS instrument. The water used for 
ICP-MS analysis was doubly deionized (DDW) using a Millipore Milli-Q water 
purification system and a USF Elga UHQ water deionizer. The iridium Specpure 
plasma standard (Alfa Aesar, 1000 ppm in 10% HCl) was diluted with 3% HNO3 
DDW to freshly prepare calibrants at concentrations 1000, 800, 400, 200, 100, 50, 10, 
1 and 0.1 ppb. The ICP-MS instrument was set to detect 
193
Ir with typical detection 
limits of ca. 8 ppt using no gas mode. 
Cell Culture and Cytotoxicity. The A2780 ovarian cell line was obtained from the 
ECACC (European Collection of Animal Cell Culture, Salisbury, UK). The cells were 
maintained in RPMI 1640 media which was supplemented with 10% fetal calf serum, 
1% L-glutamine, and 1% penicillin/streptomycin. All cells were grown at 310 K in a 
humidified atmosphere containing 5% CO2. 
Stock solutions of the Ir
III
 complexes were firstly prepared in DMSO to assist 
dissolution, and then diluted into 0.9% saline and medium (1:1). After plating 5000 
A2780 cells per well on day 1, Ir
III
 complexes were added to the cancer cells on day 3 
at concentrations ranging from 0.05 μM to 100 μM, depending on the preliminary 
activity data obtained in screening assays. Cells were exposed to the complexes for 24 
h, washed with PBS, supplied with fresh medium, allowed to grow for three doubling 
times (72 h), and then the protein content (proportional to cell survival) measured 
using the sulforhodamine B (SRB) assay.
61
 The standard errors are based on two 
independent experiments of three replicates each. 
log P Determination. Octanol-saturated water (OSW) and water-saturated octanol 
(WSO) were prepared using analytical grade octanol and 0.2 M aqueous NaCl 
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solution (to suppress hydrolysis of the chlorido complexes). Aliquots of stock 
solutions of iridium complexes in OSW were added to equal volumes of WSO and 
shaken in an IKA Vibrax VXC basic shaker for 4 h at 500 g/min to allow partition at 
ambient temperature (∼298 K). The aqueous layer was carefully separated from the 
octanol layer for iridium analysis. 
193
Ir was quantified from aliquots taken from the 
octanol-saturated aqueous samples before and after partition. Partition coefficients of 
Ir
III
 complexes were calculated using the equation log P = log ([Ir]WSO/[Ir]OSW), where 
[Ir]WSO was obtained by subtraction of the Ir content of the aqueous layer after 
partition from the Ir content of the aqueous layer before partition. 
Cell Accumulation, Cellular Distribution, and DNA Binding in A2780 Human 
Carcinoma Cells. A2780 cells were plated at a density of 5×10
6
 cells/100 mm Petri 
dish in 9 mL of culture medium on day 1 (three dishes were prepared per compound 
tested, and three untreated control dishes, in two independent experiments). On day 2 
cells were exposed to the Ir
III
 complexes 4 6. Stock solutions of the iridium 
compounds were prepared fresh in DMSO and diluted in 0.9% saline and medium 
(1:1; 0.5% v/v DMSO final concentration) to a final concentration of Ir on the plates 
of 5 μM. After 24 h of drug exposure at 310 K on a 5% CO2 incubator, the 
drug-containing medium was removed and the cells were washed, trypsinized, and 
counted using a haemocytometer. One-third of the cells were centrifuged, quickly 
washed with PBS, and stored at 253 K for determination of total cell accumulation 
(the net effect of uptake and efflux) of iridium. Another third of the samples was used 
for cytosol, nucleus, membrane/particulate and cytoskeleton fractionation, using a 
FractionPREP™ cell fractionation kit from BioVision (Mountain View, CA). The last 
third of the samples was used for quantification of Ir bound to DNA using the 
Nucleon genomic DNA extraction kit (GE healthcare, Amersham, UK; BACC-1 
protocol). All the cell pellets and solid cell fractions were digested in freshly distilled 
72% HNO3 in Wheaton V-Vials with a PTFE-faced rubber lined cap (Sigma-Aldrich) 
for 16 h at 373 K. After cooling, the samples were diluted with DDW to a maximum 
final concentration of 7.2% HNO3 (suitable for ICP-MS analysis) prior quantification 
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of iridium. 
Sequence Preference of DNA Adducts. The primer extension footprinting assay 
was used to evaluate the sequence selectivity of DNA modification by complexes 4–6. 
A fragment of pSP73KB DNA linearized by HpaI (2464 bp) was incubated with Ir
III
 
complexes in 10 mM NaClO4 for 24 h at 310 K to obtain rb = 0.01 (bound Ir/base). 
The excess of drug was removed by ethanol precipitation. Circum VentTM Thermal 
Cycle Sequencing Kit with Vent(exo
-
) DNA polymerase was used along with the 
protocol for thermal cycle DNA sequencing with 5′ end-labeled 20-mer SP6 primer 
recommended by the manufacturer with small modifications.
62
 The synthesis products 
were separated by electrophoresis on a denaturing polyacrylamide (PAA) gel [6% 
polyacrylamide (PAA)/8M urea]; sequence ladders were obtained in parallel using 
untreated control DNA fragment. 
Fluorescence Measurements. These measurements were performed on a 
Shimadzu RF 40 spectrofluorophotometer using a 1 cm quartz cell. Fluorescence 
measurements of CT DNA modified by Ir
III
 complexes, cisplatin or [Pt(dien)Cl]Cl 
(dien = diethylenetriamine), in the presence of EtBr, were performed at an excitation 
wavelength of 546 nm, and the emitted fluorescence was analyzed at 590 nm. The 
fluorescence intensity was measured at 298 K in 0.4 M NaCl to avoid secondary 
binding of EtBr to DNA.
63
 The concentrations were 0.01 mg/mL for DNA and 0.04 
mg/mL for EtBr, which corresponded to the saturation of all intercalation sites for 
EtBr in DNA.
63a
 
Viscometry. The relative viscosity of the solutions of CT DNA nonmodified or 
modified by complexes 4–6 at the concentration of 150 µg/mL was measured by 
microviscometry (AMVn Automated Micro Viscometer, Anton Paar GmbH, Austria) 
using a 1.6-mm capillary tube at 310 K. The densities of the solutions were measured 
using a Density Meter DMA 4500 instrument (Anton Paar GmbH, Austria). 
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